Clinical Trial Update: Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. [Phase 2]

View source ↗

Summary

Phase II trial investigating an anti-PD1 epigenetic therapy in non-small cell lung cancer has completed. Results were posted in May 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Non-Small Cell Lung Cancer, Epigenetic Therapy | Phase 2 | Status: COMPLETED | Results posted: 2024-05-03